{"id":1438,"date":"2019-04-02T09:00:00","date_gmt":"2019-04-02T09:00:00","guid":{"rendered":"https:\/\/lee-pharm.com\/regenerx-and-lees-pharm-to-accelerate-rgn-259-development-in-china\/"},"modified":"2026-09-24T10:22:21","modified_gmt":"2026-09-24T10:22:21","slug":"regenerx-and-lees-pharm-to-accelerate-rgn-259-development-in-china","status":"publish","type":"post","link":"https:\/\/lee-pharm.com\/en\/regenerx-and-lees-pharm-to-accelerate-rgn-259-development-in-china\/","title":{"rendered":"RegeneRx and Lee\u2019s Pharm to Accelerate RGN-259 Development in China"},"content":{"rendered":"<p>ROCKVILLE, Md. and Hong Kong (April 2, 2019) \u2013 RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (\u201cthe Company\u201d or \u201cRegeneRx\u201d), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee\u2019s Pharmaceutical Holdings Limited (\u201cLee\u2019s Pharm\u201d), a Hong Kong based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications. Lee\u2019s Pharm previously licensed RGN-259, RegeneRx\u2019s sterile, preservative-free, topical eye drop developed for the treatment of ophthalmic indications such as dry eye syndrome (DES), neurotrophic keratitis (NK), and other persistent corneal disorders, in China, Taiwan, Macau, and Hong Kong.<\/p>\n<p class=\"lpns-download-wrap\"><a class=\"lpns-download\" href=\"https:\/\/www.leespharm.com\/wp-content\/uploads\/2019\/10\/Press_Release_RGNX_REV2.pdf\" target=\"_blank\" rel=\"noopener\">\u0e14\u0e32\u0e27\u0e19\u0e4c\u0e42\u0e2b\u0e25\u0e14\u0e02\u0e48\u0e32\u0e27\u0e09\u0e1a\u0e31\u0e1a\u0e40\u0e15\u0e47\u0e21 (PDF)<\/a><\/p>\n<p><em>\u0e17\u0e35\u0e48\u0e21\u0e32: <a href=\"https:\/\/www.leespharm.com\/media\/?filter=Recent\" target=\"_blank\" rel=\"noopener\">Lee&#8217;s Pharmaceutical Holdings \u2013 News &amp; Media<\/a><\/em><\/p>","protected":false},"excerpt":{"rendered":"<p>ROCKVILLE, Md. and Hong Kong (April 2, 2019) \u2013 RegeneRx Biopharmaceuticals, Inc. (OTCQB: RGRX) (\u201cthe Company\u201d or \u201cRegeneRx\u201d), a clinical-stage drug development company focused on tissue protection, repair and regeneration, and Lee\u2019s Pharmaceutical Holdings Limited (\u201cLee\u2019s Pharm\u201d), a Hong Kong based pharmaceutical company, are accelerating development of RGN-259 in China for ophthalmic indications. Lee\u2019s Pharm [&hellip;]<\/p>\n","protected":false},"author":1,"featured_media":1439,"comment_status":"open","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"footnotes":""},"categories":[32,29],"tags":[],"class_list":["post-1438","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-lees-pharm-group-news","category-news"],"_links":{"self":[{"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/posts\/1438","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/users\/1"}],"replies":[{"embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/comments?post=1438"}],"version-history":[{"count":1,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/posts\/1438\/revisions"}],"predecessor-version":[{"id":1440,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/posts\/1438\/revisions\/1440"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/media\/1439"}],"wp:attachment":[{"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/media?parent=1438"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/categories?post=1438"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/lee-pharm.com\/en\/wp-json\/wp\/v2\/tags?post=1438"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}